Aurealis Therapeutics Raises CHF 8 Million to Complete Phase 2 Clinical Studies in Chronic Wounds and Accelerate Oncology Program
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, has raised CHF 8 million from existing investors and shareholders. The funds will be primarily used to complete Phase 2 clinical studies with Aurealis lead product AUP-16 for Chronic Wounds, such as Diabetic […]
